

Yeoungjee Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4072763/publications.pdf>

Version: 2024-02-01

136
papers

3,979
citations

147801

31
h-index

149698

56
g-index

137
all docs

137
docs citations

137
times ranked

3627
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. <i>Journal of Vascular Access</i> , 2024, 25, 193-202.	0.9	2
2	Associations, microbiology and outcomes of pre-training peritoneal dialysis-related peritonitis. <i>Peritoneal Dialysis International</i> , 2023, 43, 173-181.	2.3	2
3	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. <i>Peritoneal Dialysis International</i> , 2022, 42, 279-287.	2.3	9
4	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 407-416.	2.9	3
5	Perspectives on ability to work from patientsâ€™ receiving dialysis and caregivers: analysis of data from the global SONG initiative. <i>Journal of Nephrology</i> , 2022, 35, 255-266.	2.0	7
6	Representativeness of the PDOPPS cohort compared to the Australian PD population. <i>Peritoneal Dialysis International</i> , 2022, 42, 403-414.	2.3	2
7	Incremental Versus Standard (Full-Dose) Peritoneal Dialysis. <i>Kidney International Reports</i> , 2022, 7, 165-176.	0.8	15
8	The case for increased peritoneal dialysis utilization in low- and lower-middle-income countries. <i>Nephrology</i> , 2022, 27, 391-403.	1.6	10
9	Epidemiology of haemodialysis outcomes. <i>Nature Reviews Nephrology</i> , 2022, 18, 378-395.	9.6	96
10	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. <i>Peritoneal Dialysis International</i> , 2022, 42, 110-153.	2.3	209
11	A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.	4.5	4
12	Establishing a core outcome measure for life participation in patients receiving peritoneal dialysis: A Standardised Outcomes in Nephrologyâ€™ Peritoneal Dialysis consensus workshop report. <i>Peritoneal Dialysis International</i> , 2022, 42, 562-570.	2.3	7
13	Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrologyâ€™ Peritoneal Dialysis Consensus Workshop Report. <i>Kidney International Reports</i> , 2022, , .	0.8	1
14	Patient and caregiver perspectives on burnout in peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2021, 41, 484-493.	2.3	14
15	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€™ Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	1.9	21
16	Patient-led identification and prioritization of exercise interventions for fatigue on dialysis: a workshop report. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 831-839.	2.9	11
17	Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2021, 41, 226-235.	2.3	1
18	Perspectives on blood pressure by patients on haemo- and peritoneal dialysis. <i>Nephrology</i> , 2021, 26, 62-69.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Longer antibiotic durations for treating peritoneal dialysis-associated peritonitis: helpful or harmful?. CKJ: Clinical Kidney Journal, 2021, 14, 735-738.	2.9	0
20	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, The, 2021, 372, m4573.	6.0	322
21	Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodialysis International, 2021, 25, 322-332.	0.9	10
22	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 315-325.	1.9	62
23	Impact of deceased donor with acute kidney injury on subsequent kidney transplant outcomesâ€”an ANZDATA registry analysis. PLoS ONE, 2021, 16, e0249000.	2.5	10
24	Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS ONE, 2021, 16, e0252479.	2.5	4
25	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	5.2	13
26	Kidney Transplant Outcomes in elderly Recipients: An Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry Study. Transplantation Proceedings, 2021, 53, 1915-1926.	0.6	5
27	Standardised Outcomes in Nephrology â€” Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials, 2021, 22, 612.	1.6	12
28	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
29	Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. The Cochrane Library, 2021, 2021, CD012899.	2.8	15
30	Perspectives on mental health among patients receiving dialysis. Nephrology Dialysis Transplantation, 2021, 36, 1317-1325.	0.7	12
31	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
32	Scope and heterogeneity of outcomes reported in randomized trials in patients receiving peritoneal dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1817-1825.	2.9	4
33	â€”A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	1.9	5
34	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1612-1621.	0.9	12
35	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1622-1635.	0.9	47
36	Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrology Dialysis Transplantation, 2020, 35, 1949-1958.	0.7	46

#	ARTICLE	IF	CITATIONS
37	Multicenter registry analysis comparing survival on home hemodialysis and kidney transplant recipients in Australia and New Zealand. <i>Nephrology Dialysis Transplantation</i> , 2020, 36, 1937-1946.	0.7	6
38	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	4.5	66
39	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2020, 76, 361-373.	1.9	23
40	NT-proBNP Concentration and Early Cardiac Dysfunction in Patients Receiving Dialysis: A Prospective Cohort Study. <i>CardioRenal Medicine</i> , 2020, 10, 323-332.	1.9	0
41	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	1.9	10
42	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2020, 76, 213-223.	1.9	16
43	Patient and center characteristics associated with kidney transplant outcomes: a binational registry analysis. <i>Transplant International</i> , 2020, 33, 1667-1680.	1.6	4
44	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€”Children and Adolescents (SONG-KIDS) consensus workshops. <i>Kidney International</i> , 2020, 98, 553-565.	5.2	58
45	Effect of patient- and center-level characteristics on uptake of home dialysis in Australia and New Zealand: a multicenter registry analysis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1938-1949.	0.7	14
46	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	2.3	24
47	Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review. <i>Peritoneal Dialysis International</i> , 2020, 40, 132-140.	2.3	26
48	Raising the standard of trial registration, conduct, and reporting. <i>Peritoneal Dialysis International</i> , 2020, 40, 112-114.	2.3	1
49	Targeted Education Approach to improve Peritoneal Dialysis Outcomes (TEACH-PD): A feasibility study. <i>Peritoneal Dialysis International</i> , 2020, 40, 153-163.	2.3	9
50	â€œCan I go to Glasgow?â€• Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). <i>Peritoneal Dialysis International</i> , 2020, 40, 12-25.	2.3	5
51	A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study. <i>Blood Purification</i> , 2020, 49, 468-478.	1.8	38
52	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14 Diseases, 2020, 75, 404-412.	1.9	92
53	Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 755-764.	0.7	19
54	Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 12, CD012913.	2.8	12

#	ARTICLE	IF	CITATIONS
55	Perspectives on life participation by young adults with chronic kidney disease: an interview study. <i>BMJ Open</i> , 2020, 10, e037840.	1.9	23
56	Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study. <i>PLoS ONE</i> , 2020, 15, e0242254.	2.5	8
57	Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry. <i>PLoS ONE</i> , 2019, 14, e0221531.	2.5	7
58	Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. <i>Nephrology</i> , 2019, 24, 1214-1224.	1.6	20
59	GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210246.	2.5	7
60	An Intervention Design: Supporting Skills Development for Peritoneal Dialysis Trainers. <i>Peritoneal Dialysis International</i> , 2019, 39, 134-141.	2.3	18
61	Standardized Outcomes in Nephrology Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	5.2	20
62	An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis. <i>Kidney International</i> , 2019, 96, 699-710.	5.2	73
63	Urgent-start peritoneal dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 631-640.	2.0	19
64	Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 74-83.	4.5	101
65	Comparison of graft and patient outcomes following kidney transplantation in extended hour and conventional haemodialysis patients. <i>Nephrology</i> , 2019, 24, 111-120.	1.6	1
66	Outcome Measures Used to Report Kidney Function in Studies Investigating Surgical Management of Kidney Tumours: A Systematic Review. <i>European Urology Focus</i> , 2019, 5, 1074-1084.	3.1	3
67	Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. <i>The Cochrane Library</i> , 2019, 2019, CD004680.	2.8	14
68	In Reply to "The Importance of Icodextrin Use for Technique and Patient Survival in Peritoneal Dialysis". <i>American Journal of Kidney Diseases</i> , 2018, 72, 309-310.	1.9	2
69	Outcomes of Acinetobacter Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	2.3	12
70	Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 2018, , .	2.8	1
71	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 188-197.	1.9	85
72	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. <i>American Journal of Kidney Diseases</i> , 2018, 71, 814-821.	1.9	66

#	ARTICLE	IF	CITATIONS
73	Teaching peritoneal dialysis in Australia: An opportunity for improvement. <i>Nephrology</i> , 2018, 23, 259-263.	1.6	15
74	Practice of Peritoneal Dialysis Catheter Flushing in Australia and New Zealand: Multi-Center Cross-Sectional Survey. <i>Peritoneal Dialysis International</i> , 2018, 38, 98-103.	2.3	4
75	Biocompatible dialysis fluids for peritoneal dialysis. <i>The Cochrane Library</i> , 2018, 2018, CD007554.	2.8	46
76	Early Peritoneal Dialysis Technique Failure: Review. <i>Peritoneal Dialysis International</i> , 2018, 38, 319-327.	2.3	20
77	Centre Effects in Peritoneal Dialysis. , 2018, , .		0
78	PD Solutions and Peritoneal Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1455-1457.	4.5	3
79	The Relationship between Body Mass Index and Organism-Specific Peritonitis. <i>Peritoneal Dialysis International</i> , 2018, 38, 206-214.	2.3	9
80	FP495PATIENT AND CAREGIVER PRIORITIES FOR OUTCOMES IN PERITONEAL DIALYSIS: AN INTERNATIONAL NOMINAL GROUP STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i205-i205.	0.7	0
81	Clinical Studies of Interventions to Mitigate Cardiovascular Risk in Peritoneal Dialysis Patients. <i>Seminars in Nephrology</i> , 2018, 38, 277-290.	1.6	24
82	Associations between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the <i>bal</i> ANZ Trial. <i>Peritoneal Dialysis International</i> , 2018, 38, 349-355.	2.3	8
83	Peritoneal Dialysis-Related Peritonitis: Atypical and Resistant Organisms. <i>Seminars in Nephrology</i> , 2017, 37, 66-76.	1.6	15
84	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 397-406.	2.3	14
85	Association between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The <i>Bal</i> ANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 407-413.	2.3	6
86	Centre effects and peritoneal dialysis-related peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 913-915.	0.7	8
87	Early and Late Patient Outcomes in Urgent-Start Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 414-419.	2.3	73
88	Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The <i>Bal</i> ANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 283-289.	2.3	40
89	Evidence for Biocompatible Peritoneal Dialysis Solutions. <i>Contributions To Nephrology</i> , 2017, 189, 91-101.	1.1	8
90	EARLY PERITONITIS AND ITS OUTCOME IN INCIDENT PERITONEAL DIALYSIS PATIENTS. <i>Peritoneal Dialysis International</i> , 2017, , pdi.2017.00029.	2.3	11

#	ARTICLE	IF	CITATIONS
91	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 619-626.	2.3	18
92	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1090-1099.	4.5	94
93	The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-10.	1.2	14
94	Standardised Outcomes in Nephrology Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. <i>Trials</i> , 2017, 18, 560.	1.6	20
95	Early Onset Peritoneal Dialysis-Related Peritonitis. <i>Journal of Clinical & Experimental Nephrology</i> , 2017, 2, .	0.1	3
96	Center-Specific Factors Associated with Peritonitis Risk—A Multi-Center Registry Analysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 509-518.	2.3	54
97	Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand. <i>Peritoneal Dialysis International</i> , 2016, 36, 472-477.	2.3	28
98	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 313.	7.4	329
99	Temporal Changes in Deceased Kidney Donor Characteristics in Australia. <i>Transplantation Direct</i> , 2016, 2, e112.	1.6	3
100	Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions. <i>Peritoneal Dialysis International</i> , 2016, 36, 146-153.	2.3	3
101	Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction. <i>Peritoneal Dialysis International</i> , 2016, 36, 16-25.	2.3	8
102	Neutrophil-lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. <i>Renal Failure</i> , 2016, 38, 70-76.	2.1	39
103	Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease: An Update. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 12-32.	0.8	4
104	Honey in the Prevention and Treatment of Infection in the CKD Population: A Narrative Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	1.2	5
105	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2015, 35, 222-228.	2.3	19
106	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 35-42.	2.3	23
107	Economic Evaluation of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions Compared With Standard Solutions: A Secondary Analysis of the balANZ Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 773-779.	1.9	16
108	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1897-1904.	0.7	20

#	ARTICLE	IF	CITATIONS
109	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 159-171.	2.3	7
110	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2014, 34, 219-226.	2.3	14
111	Clinical Causes of Inflammation in Peritoneal Dialysis Patients. <i>International Journal of Nephrology</i> , 2014, 2014, 1-9.	1.3	34
112	Outcomes of Nephrologist-Inserted Peritoneal Catheters in Indigenous Patients from Far North Queensland. <i>Peritoneal Dialysis International</i> , 2014, 34, 663-667.	2.3	5
113	Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 192-197.	2.0	9
114	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.7	34
115	Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. <i>BMC Nephrology</i> , 2014, 15, 8.	1.8	46
116	Biocompatible dialysis fluids for peritoneal dialysis. <i>The Cochrane Library</i> , 2014, , CD007554.	2.8	85
117	Peritoneal Dialysis-Related Peritonitis: Towards Improving Evidence, Practices, and Outcomes. <i>American Journal of Kidney Diseases</i> , 2014, 64, 278-289.	1.9	178
118	The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. <i>Kidney International</i> , 2013, 84, 969-979.	5.2	73
119	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	4.5	26
120	Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1899-1907.	0.7	75
121	Is Female Sex Really a Risk Factor for Infectious Death in Peritoneal Dialysis?. <i>Peritoneal Dialysis International</i> , 2013, 33, 475-478.	2.3	5
122	Non-Candidal Fungal Peritonitis in Far North Queensland: A Case Series. <i>Peritoneal Dialysis International</i> , 2013, 33, 559-564.	2.3	8
123	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. <i>Peritoneal Dialysis International</i> , 2013, 33, 75-85.	2.3	17
124	Association of micropapillary urothelial carcinoma of the bladder and <sc>BK</sc> viraemia in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2013, 15, 283-289.	1.7	37
125	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	1.3	18
126	Trials (and Tribulations) of Biocompatible Peritoneal Dialysis Fluids. <i>Peritoneal Dialysis International</i> , 2012, 32, 247-251.	2.3	3

#	ARTICLE	IF	CITATIONS
127	Large urate cystolith associated with Proteus urinary tract infection. <i>Kidney International</i> , 2012, 81, 802.	5.2	8
128	Weekend Compared with Weekday Presentations of Peritoneal Dialysis-associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2012, 32, 516-524.	2.3	16
129	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2028-2036.	0.7	31
130	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. <i>BMC Nephrology</i> , 2012, 13, 41.	1.8	27
131	DABIGATRAN MAY NOT BE AN EFFECTIVE ANTICOAGULANT FOR HAEMODIALYSIS. <i>Nephrology</i> , 2010, 15, 594-595.	1.6	2
132	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. <i>Kidney International</i> , 2010, 77, 904-912.	5.2	154
133	Acute hydrothorax complicating peritoneal dialysis: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 355.	0.8	15
134	Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients. <i>BMC Nephrology</i> , 2009, 10, 32.	1.8	10
135	Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 0, , .	2.8	2
136	Dialysis modality utilization patterns and mortality in older persons initiating dialysis in Australia and New Zealand. <i>Nephrology</i> , 0, , .	1.6	0